Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 2/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
| ▸ | FYN | P06241 | 2/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | KMO | O15229 | 1/20 | 0.34 |
| ▸ | DHFR | P00374 | 1/20 | 0.34 |
| ▸ | ACP1 | P24666 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL4480660 | 0.99 | HPGDS (0.41) | HPGDSCYP11B1HSD11B1IDO1MAP4K4 | |
| SCHEMBL2678219 | 0.98 | HPGDS (0.43) | HPGDSCYP11B1HSD11B1IDO1MAP4K4 | |
| SCHEMBL2679400 | 0.95 | HPGDS (0.45) | HPGDSCYP11B1HSD11B1IDO1MAP4K4 | |
| SCHEMBL5156396 | 0.86 | KDM1A (0.43) | IDO1 | |
| SCHEMBL4463296 | 0.85 | HSD11B1 (0.40) | HSD11B1CHRNB2CHRNA7CHRNA4 | |
| Bromide SCHEMBL4466442 | 0.85 | KDM1A (0.42) | IDO1 | |
| Bromide SCHEMBL4471147 | 0.84 | HSD11B1 (0.39) | HSD11B1CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL2676629 | 0.82 | KDM1A (0.47) | IDO1KMO | |
| SCHEMBL2678305 | 0.82 | KDM1A (0.47) | HPGDSFYNCHRNB2CHRNA4 | |
| SCHEMBL2678702 | 0.82 | NPC1 (0.39) | CYP11B1HSD11B1PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7585974-B2 | Derivatives of 5-(pyridin-3-yl)-1-azabicyclo[3.2.1]octane, their preparation and their therapeutic application | SANOFI-AVENTIS (FR) | 2009-09-08 | — | — | US | claimed |
| US-20070185137-A1 | Derivatives of 5-(pyridin-3-yl)-1-azabicyclo[3.2.1]octane, their preparation and their therapeutic application | SANOFI-AVENTIS (FR) | 2007-08-09 | — | — | US | claimed |
| EP-1465893-B1 | DERIVATIVES OF 5-(PYRIDIN-3-YL)-1-AZABICYCLO (3.2.1) OCTANE, THE PREPARATION THEREOF AND THE APPLICATION OF SAME IN THERAPEUTICS | SANOFI AVENTIS (FR) | 2007-02-28 | — | — | EP | claimed |
| US-7585974-B2 | Derivatives of 5-(pyridin-3-yl)-1-azabicyclo[3.2.1]octane, their preparation and their therapeutic application | SANOFI-AVENTIS (FR) | 2009-09-08 | — | — | US | disclosed |
| US-20070185137-A1 | Derivatives of 5-(pyridin-3-yl)-1-azabicyclo[3.2.1]octane, their preparation and their therapeutic application | SANOFI-AVENTIS (FR) | 2007-08-09 | — | — | US | disclosed |
| US-7223750-B2 | Derivatives of 5-(pyridin-3-yl)-1-azabicyclo[3.2.1]octane, the preparation thereof and the application of same in therapeutics | SANOFI-AVENTIS (FR) | 2007-05-29 | — | — | US | disclosed |
| EP-1465893-B1 | DERIVATIVES OF 5-(PYRIDIN-3-YL)-1-AZABICYCLO (3.2.1) OCTANE, THE PREPARATION THEREOF AND THE APPLICATION OF SAME IN THERAPEUTICS | SANOFI AVENTIS (FR) | 2007-02-28 | — | — | EP | disclosed |
| US-20050020568-A1 | Derivatives of 5-(pyridin-3-yl)-1-azabicyclo[3.2.1] octane, the preparation thereof and the application of same in therapeutics | SANOFI (FR) | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185137-A1 | Derivatives of 5-(pyridin-3-yl)-1-azabicyclo[3.2.1]octane, their preparation and their therapeutic application | PAICS, CYC1, AADAC | HPGDS 933/4885CYP11B1 136/4885HSD11B1 1965/4885 |
| US-20050020568-A1 | Derivatives of 5-(pyridin-3-yl)-1-azabicyclo[3.2.1] octane, the preparation thereof and the application of same in therapeutics | PAICS, NAT1, TPMT | HPGDS 883/4885CYP11B1 97/4885HSD11B1 1882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.